Ian Reynolds, PhD, focuses on drug discovery for neurological and neurodegenerative diseases. Prior to his tenure at Rewind Therapeutics, he led the CNS Discovery group at Teva Pharmaceuticals. At Knopp, He also led team working on therapeutics for amyotrophic lateral sclerosis (ALS), Parkinson's, stroke, Alzheimer's disease and ophthalmology at Knopp and Merck.

Dr. Reynolds has extensive experience in academic research focused on neurodegenerative disease, including Parkinson's and stroke. The academic expertise includes substantial time leading and administering graduate education in pharmacology and neuroscience at the University of Pittsburgh. Dr. Reynolds received his undergraduate degree from the University of Leeds and his doctorate from the Johns Hopkins University School of Medicine and completed his post-doctoral fellowship in neuropharmacology at the University of Chicago.